Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from JOINN Laboratories (China) Co., Ltd. Class H ( (HK:6127) ).
JOINN Laboratories has announced its unaudited interim results for the first half of 2025, reporting a significant decrease in revenue by 21.3% compared to the same period in 2024. Despite the drop in revenue, the company turned a profit of RMB 60,932,000, a notable recovery from a loss of RMB 172,238,000 in the previous year, indicating improved operational efficiency and financial management.
The most recent analyst rating on (HK:6127) stock is a Hold with a HK$14.30 price target. To see the full list of analyst forecasts on JOINN Laboratories (China) Co., Ltd. Class H stock, see the HK:6127 Stock Forecast page.
More about JOINN Laboratories (China) Co., Ltd. Class H
JOINN Laboratories (China) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical and biotechnology industry. The company focuses on providing comprehensive laboratory services and solutions, including research and development, to support the pharmaceutical and biotechnology sectors.
Average Trading Volume: 8,959,998
Technical Sentiment Signal: Buy
Current Market Cap: HK$25.44B
For an in-depth examination of 6127 stock, go to TipRanks’ Overview page.